Alpha-GPC
A multicenter RCT in mild-to-moderate Alzheimer's dementia (De Jesus Moreno, 2003, n=261) found 1200mg/day improved ADAS-Cog, MMSE and global scores versus placebo at 90 and 180 days, and a 2023 meta-analysis supports benefit in cerebrovascular cognitive impairment. In healthy men, a single 315–630mg dose improved Stroop performance but not N-Back or Flanker (Kerksick 2024). Sports trials are inconsistent: a lower-body force gain after 6 days at 600mg (Bellar 2015), no strength effect at 250–500mg for 7 days, and no power-output effect after a single 630mg dose.
Evidence reviewed:
Mechanism of action
Alpha-GPC (alpha-glycerylphosphorylcholine) is the most bioavailable choline precursor. It delivers choline directly across the blood-brain barrier, where it is used to synthesise acetylcholine. It also supports cell membrane phospholipid synthesis. It is often marketed for growth hormone release, but a 2024 RCT at 630mg found no growth hormone difference versus placebo.
Clinical evidence summary
A multicenter RCT in mild-to-moderate Alzheimer's dementia (De Jesus Moreno, 2003, n=261) found 1200mg/day improved ADAS-Cog, MMSE and global scores versus placebo at 90 and 180 days, and a 2023 meta-analysis supports benefit in cerebrovascular cognitive impairment. In healthy men, a single 315–630mg dose improved Stroop performance but not N-Back or Flanker (Kerksick 2024). Sports trials are inconsistent: a lower-body force gain after 6 days at 600mg (Bellar 2015), no strength effect at 250–500mg for 7 days, and no power-output effect after a single 630mg dose.
Human effect matrix
Based on human clinical trials only. Animal and in-vitro data excluded.
| Effect | Evidence | Magnitude | Studies |
|---|---|---|---|
| Acetylcholine Synthesis | strong | Large | 2 |
| Memory & Cognition | moderate | Moderate | 2 |
| Athletic Power Output | mixed | Small | 3 |
| Neuroprotection | moderate | Moderate | 2 |
Evidence key: Strong = multiple consistent RCTs · Moderate = smaller/fewer RCTs · Preliminary = early trials or small n · Mixed = conflicting results
Documented benefits
- Cognition in Alzheimer's and cerebrovascular dementia (1200mg/day)
- Acute Stroop (executive) performance in healthy men
- Raises plasma choline
Side effects & cautions
- Well tolerated
- Headache if combined with other cholinergics
- 500mg/day significantly suppressed serum TSH (thyroid-stimulating hormone) in a 7-day trial
How to take
Stacking recommendations
Ingredients that pair well with Alpha-GPC and why.
Alpha-GPC provides immediate acetylcholine support; Lion's Mane drives long-term NGF synthesis. Neither overlaps mechanistically — a clean acute + long-term pairing.
Alpha-GPC handles acute memory encoding via acetylcholine; Bacopa handles memory consolidation and storage. Together they cover both encoding and consolidation stages of memory formation.
Huperzine A prevents acetylcholine breakdown while Alpha-GPC increases acetylcholine synthesis. Powerful combination in theory — but use with caution and low doses, as cholinergic overload (nausea, headache, muscle cramps) is a real risk. Not recommended without experience.
Frequently asked questions
Alpha-GPC vs Citicoline — which is better for focus?
Both are excellent. Alpha-GPC has a slight edge for acute cholinergic effects and is preferred for workout performance. Citicoline also provides cytidine (uridine precursor), giving it a broader neuroprotective profile. For pure focus and acetylcholine, Alpha-GPC wins slightly; for comprehensive brain health support, Citicoline is more complete. Don't stack them together — you'll get too much choline activity.
Is it safe to combine Alpha-GPC with Huperzine A?
Use caution. Both increase acetylcholine (Alpha-GPC via synthesis, Huperzine A via inhibiting breakdown). The combination is potent and can cause cholinergic overstimulation — symptoms include nausea, headache, excessive salivation, and muscle cramps. If combining, use lower doses of each (e.g. 200mg Alpha-GPC + 50mcg Huperzine A) and do not take daily.
Why does Alpha-GPC powder go sticky?
Alpha-GPC is highly hygroscopic — it absorbs water from the air quickly. This is normal and doesn't affect potency. Store in an airtight container in a cool, dry place. Capsule form avoids this problem entirely.
Is there a cardiovascular risk with Alpha-GPC?
Unresolved. The CARDIA cohort study (published 2024) linked higher plasma choline — not alpha-GPC supplements — with incident cardiovascular disease, while a meta-analysis of dietary choline intake found no association. No study has tested alpha-GPC supplementation directly for cardiovascular outcomes. If you have cardiovascular disease, discuss it with your doctor.
Top stacks containing Alpha-GPC
Alpha-GPC in Australia
Alpha-GPC (choline alfoscerate) does not appear under any of its names in the current TGA Therapeutic Goods (Permissible Ingredients) Determination (No. 2) 2026 (checked 2026-10-08) -- the instrument that lists the ingredients allowed in listed and assessed listed medicines. The TGA states that 'if an ingredient isn't listed in the Determination, it can't be used in listed or assessed listed medicines.' An alpha-GPC product sold to an Australian buyer is therefore not an AUST L listed medicine, whatever route it reaches them by.
Why alpha-GPC can't carry an AUST L number
This site searched the full text of the current Determination (No. 2 2026, Compilation No. 1 of 17 September 2026, all six volumes as published on the Federal Register of Legislation; searched 2026-10-08) and found no entry under 'alpha-GPC', 'choline alfoscerate', 'glycerophosphorylcholine', 'glycerophosphocholine', 'phosphorylcholine', 'phosphocholine' or 'GPC'; the choline forms Schedule 1 does list are item 1363 choline bitartrate (purpose codes A, E: active ingredient or excipient), item 1364 choline dihydrogen citrate (A, 'Only for use in oral medicines.'), item 3866 phosphatidyl choline (E: excipient only) and item 1428 citicoline (A; until 20 June 2027 only where Kyowa Hakko Bio Co Ltd is the sponsor or the TGA has been notified that it authorised a secondary sponsor, oral only, no more than 500 milligrams a day, adults only and not pregnant or lactating women), while the five glycerophosphates it lists (items 1080, 2195, 3158, 3214 and 4100) are calcium, ferric, magnesium, manganese and potassium salts, not choline compounds. Per the TGA's guidance, an ingredient absent from the Determination 'can't be used in listed or assessed listed medicines,' so a sponsor cannot obtain an AUST L number for a product whose active ingredient is alpha-GPC. Reviewed AU products on this site naming Alpha-GPC as a hero ingredient (Onnit Alpha Brain, Qualia Mind) carry no AUST L number in this site's Australian catalogue, consistent with that gap.
Products in Australia
- Qualia Mind7.3/10Personal Importation SchemeLocal price: USD 159 · 1 x Qualia Mind 2.0 - 120 count Boxed
- Alpha Brain5.2/10Personal Importation SchemeLocal price: ≈ USD 53.30/month
TGA (AUST L)
Is alpha-GPC a TGA-listed medicine ingredient in Australia?
No. Alpha-GPC does not appear in the current Permissible Ingredients Determination under any of its names (checked 2026-10-08), and the TGA states an ingredient not in the Determination 'can't be used in listed or assessed listed medicines.' A product containing it is not an AUST L listed medicine.
What does the Personal Importation Scheme say about products that are not listed medicines?
The TGA's scheme 'allows individuals to import therapeutic goods not entered in the Australian Register of Therapeutic Goods (ARTG), provided certain conditions are met,' and the TGA adds that such imports 'are not evaluated by us, meaning their safety, quality and efficacy cannot be guaranteed.'
State & territory guides
Sources: Therapeutic Goods (Permissible Ingredients) Determination (No. 2) 2026 (F2026L00707), as compiled 17 September 2026 (Compilation No. 1, F2026C00940) -- Schedule 1, items 1363 and 1364 (choline bitartrate, choline dihydrogen citrate) · Therapeutic Goods (Permissible Ingredients) Determination (No. 2) 2026 (F2026L00707), as compiled 17 September 2026 (Compilation No. 1, F2026C00940) -- Schedule 1, item 3866 (phosphatidyl choline) · Therapeutic Goods (Permissible Ingredients) Determination (No. 2) 2026 (F2026L00707), as compiled 17 September 2026 (Compilation No. 1, F2026C00940) -- Schedule 1, item 1428 (Citicoline) · TGA -- Permissible ingredients determination (overview) · Therapeutic Goods (Permissible Ingredients) Determination (No. 2) 2026 (F2026L00707), as compiled 17 September 2026 (Compilation No. 1, F2026C00940) -- Schedule 1 heading · TGA -- Personal Importation Scheme · TGA -- Personal Importation Scheme
Regulatory note
Therapeutic goods available in Australia are regulated by the Therapeutic Goods Administration (TGA). AUST L–listed products carry pre-approved permitted indications; AUST R–registered products are higher-evidence. Imported products without TGA listing are not assessed by Australian regulators. This page is editorial, not promotional, and does not constitute medical advice. Always read the label and follow directions for use. Consult a qualified healthcare professional before starting any supplement.
Sources (7)expand
- PMID 36683513Activity of Choline Alphoscerate on Adult-Onset Cognitive Dysfunctions: A Systematic Review and Meta-Analysis (2023)
- PMID 12637119Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate (De Jesus Moreno, 2003) (2003)
- PMID 39683633Acute Alpha-Glycerylphosphorylcholine Supplementation Enhances Cognitive Performance in Healthy Men (2024)
- PMID 26582972The effect of 6 days of alpha glycerylphosphorylcholine on isometric strength (Bellar et al., 2015) (2015)
- PMID 29042830Evaluation of the effects of two doses of alpha glycerylphosphorylcholine on physical and psychomotor performance (2017)
- PMID 1428296A comparative study of free plasma choline levels following intramuscular administration of L-alpha-glycerylphosphorylcholine and citicoline in normal volunteers (1992)
- PMID 37865185Choline metabolites and incident cardiovascular disease in a prospective cohort of adults: Coronary Artery Risk Development in Young Adults (CARDIA) Study. (2024)